Quick Answer
NovoCure Ltd reported Cash and Equivalents of $93.55 million for fiscal year 2025.
NovoCure Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $93.55M | -42.9% |
| 2024 | $163.77M | -32.0% |
| 2023 | $240.82M | +108.8% |
| 2022 | $115.33M | -44.8% |
| 2021 | $208.80M | -11.0% |
| 2020 | $234.67M | +32.3% |
| 2019 | $177.32M | +26.1% |
| 2018 | $140.62M | +78.9% |
| 2017 | $78.59M | -21.2% |
| 2016 | $99.78M | -16.4% |
| 2015 | $119.42M | +107.3% |
| 2014 | $57.61M | -67.2% |
| 2013 | $175.89M | +404.1% |
| 2012 | $34.89M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $342.12M | +84.5% | +128.7% |
| June 30, 2025 | $149.62M | -9.2% | +17.6% |
| March 31, 2025 | $127.28M | -72.0% | -22.3% |
| December 31, 2024 | $163.77M | -32.0% | -11.7% |
| September 30, 2024 | $185.42M | +19.7% | +12.5% |
| June 30, 2024 | $164.80M | +5.0% | -63.7% |
| March 31, 2024 | $453.76M | +144.0% | +88.4% |
| December 31, 2023 | $240.82M | +108.8% | +55.5% |
- NovoCure Ltd showed a decrease of -42.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, NovoCure Ltd’s cash and equivalents has grown by 168.1% (from $34.89 million to $93.55 million).
- The most recent figure is from NovoCure Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: